Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2011

Open Access 01-12-2011 | Research

Effect of ultrasound on herpes simplex virus infection in cell culture

Authors: Motoko Shintani, Gen Takahashi, Masakazu Hamada, Shyusuke Okunaga, Soichi Iwai, Yoshiaki Yura

Published in: Virology Journal | Issue 1/2011

Login to get access

Abstract

Background

Ultrasound has been shown to increase the efficiency of gene expression from retroviruses, adenoviruses and adeno-associated viruses. The effect of ultrasound to stimulate cell membrane permeabilization on infection with an oncolytic herpes simplex virus type 1 (HSV-1) was examined.

Results

Vero monkey kidney cells were infected with HSV-1 and exposed to 1 MHz ultrasound after an adsorption period. The number of plaques was significantly greater than that of the untreated control. A combination of ultrasound and microbubbles further increased the plaque number. Similar results were obtained using a different type of HSV-1 and oral squamous cell carcinoma (SCC) cells. The appropriate intensity, duty cycle and time of ultrasound to increase the plaque number were 0.5 W/cm2, 20% duty cycle and 10 sec, respectively. Ultrasound with microbubbles at an intensity of 2.0 W/cm2, at 50% duty cycle, or for 40 sec reduced cell viability.

Conclusion

These results indicate that ultrasound promotes the entry of oncolytic HSV-1 into cells. It may be useful to enhance the efficiency of HSV-1 infection in oncolytic virotherapy.
Appendix
Available only for authorised users
Literature
1.
Martuza RL, Malick A, Market JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of genetically engineered virus mutant. Science 1991, 252: 854-856. 10.1126/science.1851332CrossRefPubMed
2.
Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000, 15: 6359-6366.
3.
Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ: Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103: 1641-1646. 10.1182/blood-2003-07-2233CrossRefPubMed
4.
Nakamori M, Fu X, Rousseau R, Chen SY, Zhang X: Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004, 9: 658-665. 10.1016/j.ymthe.2004.02.019CrossRefPubMed
5.
Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995, 1: 938-943. 10.1038/nm0995-938CrossRefPubMed
6.
Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M, Glasschroeder B, Knoll A, Getrajdman G, Kowal KJ, Jarnagin WR, Fong Y: Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006, 17: 1214-1224. 10.1089/hum.2006.17.1214CrossRefPubMed
7.
Mace AT, Ganly I, Soutar DS, Brown SM: Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 2008, 30: 1045-1051. 10.1002/hed.20840CrossRefPubMed
8.
Boucher Y, Baxter LT, Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990, 50: 4478-4484.PubMed
9.
Jain RK: Normalization of tumor vasculature: an emerging concept inantiangiogenic therapy. Science 2005, 307: 58-62. 10.1126/science.1104819CrossRefPubMed
10.
McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006, 66: 2509-2513. 10.1158/0008-5472.CAN-05-2242CrossRefPubMed
11.
Wang Y, Yuan F: Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement. Ann Biomed Eng 2006, 34: 114-127. 10.1007/s10439-005-9007-2CrossRefPubMed
12.
Lindner JR: Molecular imaging with contrast ultrasound and targeted microbubbles. J Nucl Cardiol 2004, 11: 215-221. 10.1016/j.nuclcard.2004.01.003CrossRefPubMed
13.
Kaufmann BA, Lindner JR: Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol 2007, 18: 11-16. 10.1016/j.copbio.2007.01.004CrossRefPubMed
14.
Dooley DA, Child SZ, Carstensen EL, Miller MW: The effects of continuous wave and pulsed ultrasound on rat thymocytes in vitro. Ultrasound Med Biol 1983, 9: 379-384. 10.1016/0301-5629(83)90091-1CrossRefPubMed
15.
Fechheimer M, Boylan JF, Parker S, Sisken JE, Patel GL, Zimmer SG: Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc Natl Acad Sci USA 1987, 84: 8463-8467. 10.1073/pnas.84.23.8463PubMedCentralCrossRefPubMed
16.
Newman CM, Lawrie A, Brisken AF, Cumberland DC: Ultrasound gene therapy: on the road from concept to reality. Echocardiography 2001, 18: 339-347. 10.1046/j.1540-8175.2001.00339.xCrossRefPubMed
17.
18.
Lee YH, Peng CA: Enhanced retroviral gene delivery in ultrasonic standing wave fields. Gene Ther 2005, 12: 625-633. 10.1038/sj.gt.3302444CrossRefPubMed
19.
Howard CM, Forsberg F, Minimo C, Liu JB, Merton DA, Claudio PP: Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. J Cell Physiol 2006, 209: 413-421. 10.1002/jcp.20736CrossRefPubMed
20.
Taylor SL, Rahim AA, Bush NL, Bamber JC, Porter CD: Targeted retroviral gene delivery using ultrasound. J Gene Med 2007, 9: 77-87. 10.1002/jgm.1003CrossRefPubMed
21.
Li HL, Zheng XZ, Wang HP, Li F, Wu Y, Du LF: Ultrasound-targeted microbubble destruction enhances AAV-mediated gene transfection in human RPE cells in vitro and rat retina in vivo. Gene Ther 2009, 16: 1146-1153. 10.1038/gt.2009.84CrossRefPubMed
22.
Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997, 57: 1502-1509.PubMed
23.
Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A, Nawa A, Kurata T, Sata T, Nishiyama Y: Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003, 148: 813-825. 10.1007/s00705-002-0944-xCrossRefPubMed
24.
Ogawa F, Takaoka H, Iwai S, Aota K, Yura Y: Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res 2008, 28: 3637-3645.PubMed
25.
Naito S, Obayashi S, Sumi T, Iwai S, Nakazawa M, Ikuta K, Yura Y: Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Cancer Gene Ther 2006, 13: 780-791. 10.1038/sj.cgt.7700957CrossRefPubMed
26.
Kodama T, Tomita Y, Koshiyama K, Blomley MJ: Transfection effect of microbubbles on cells in superposed ultrasound waves and behavior of cavitation bubble. Ultrasound Med Biol 2006, 32: 905-914. 10.1016/j.ultrasmedbio.2006.03.004CrossRefPubMed
27.
Tachibana K, Feril LB Jr, Ikeda-Dantsuji Y: Sonodynamic therapy. Ultrasonics 2008, 48: 253-259. 10.1016/j.ultras.2008.02.003CrossRefPubMed
28.
Iwanaga K, Tominaga K, Yamamoto K, Habu M, Maeda H, Akifusa S, Tsujisawa T, Okinaga T, Fukuda J, Nishihara T: Local delivery system of cytotoxic agents to tumors by focused sonoporation. Cancer Gene Ther 2007, 14: 354-363. 10.1038/sj.cgt.7701026CrossRefPubMed
29.
Watanabe Y, Aoi A, Horie S, Tomita N, Mori S, Morikawa H, Matsumura Y, Vassaux G, Kodama T: Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin. Cancer Sci 2008, 99: 2525-2531. 10.1111/j.1349-7006.2008.00989.xCrossRefPubMed
30.
Li T, Tachibana K, Kuroki M, Kuroki M: Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice--initial results. Radiology 2003, 229: 423-428. 10.1148/radiol.2292020500CrossRefPubMed
31.
Kopechek JA, Kim H, McPherson DD, Holland CK: Calibration of the 1-MHz Sonitron ultrasound system. Ultrasound Med Biol 2010, 36: 1762-1766. 10.1016/j.ultrasmedbio.2010.05.020PubMedCentralCrossRefPubMed
32.
Ando H, Feril LB Jr, Kondo T, Tabuchi Y, Ogawa R, Zhao QL, Cui ZG, Umemura S, Yoshikawa H, Misaki T: An echo-contrast agent, Levovist, lowers the ultrasound intensity required to induce apoptosis of human leukemia cells. Cancer Lett 2006, 242: 37-45. 10.1016/j.canlet.2005.10.032CrossRefPubMed
33.
Li YS, Reid CN, McHale AP: Enhancing ultrasound-mediated cell membrane permeabilisation (sonoporation) using a high frequency pulse regime and implications for ultrasound-aided cancer chemotherapy. Cancer Lett 2008, 266: 156-162. 10.1016/j.canlet.2008.02.041CrossRefPubMed
34.
Spear PG, Manoj S, Yoon M, Jogger CR, Zago A, Myscofski D: Different receptors binding to distinct interfaces on herpes simplex virus gD can trigger events leading to cell fusion and viral entry. Virology 2006, 344: 17-24. 10.1016/j.virol.2005.09.016CrossRefPubMed
35.
Campadelli-Fiume G, Amasio M, Avitabile E, Cerretani A, Forghieri C, Gianni T, Menotti L: The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol 2007, 17: 313-326. 10.1002/rmv.546CrossRefPubMed
36.
Reske A, Pollara G, Krummenacher C, Chain BM, Katz DR: Understanding HSV-1 entry glycoproteins. Rev Med Virol 2007, 17: 205-215. 10.1002/rmv.531CrossRefPubMed
37.
Metadata
Title
Effect of ultrasound on herpes simplex virus infection in cell culture
Authors
Motoko Shintani
Gen Takahashi
Masakazu Hamada
Shyusuke Okunaga
Soichi Iwai
Yoshiaki Yura
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-8-446

Other articles of this Issue 1/2011

Virology Journal 1/2011 Go to the issue

Research

Antiviral activity of Acacia nilotica against Hepatitis C Virus in liver infected cells

Short report

Hepatitis E Virus infection in HIV-infected patients with elevated serum transaminases levels

Research

Isolation and characterization of a novel alphanodavirus

Short report

Molecular epidemiology of novel swine origin influenza virus (S-OIV) from Gwalior, India, 2009

Research

Improved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses

Research

A common set of developmental miRNAs are upregulated in Nicotiana benthamiana by diverse begomoviruses
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits